NSE / BSEHealthcare
β‚Ή7155.45-10.85-0.15%
P/E88.9Mkt Capβ‚Ή20.55 K CrEV/EBITDA86.6

AstraZeneca Pharma India Ltd.

P/E88.9Mkt Capβ‚Ή20.55 K CrEV/EBITDA86.6
Company Profile

AstraZeneca Pharma India Limited, a biopharmaceutical company, manufactures, markets, and trades in pharmaceutical products in India and internationally. It provides medicines for cardiovascular, renal, metabolic, and immunological conditions; oncology medicines under the TAGRISSO, Lynparza, ENHERTU, IMFINZI, and Zoladex brand names; rare diseases medicines under the Koselugo brand name; and respiratory medicines under the Symbicort and Fasenra brand names. The company also offers medicines for diabetes; and clinical trial services. The company was incorporated in 1979 and is based in Bengaluru, India. AstraZeneca Pharma India Limited is a subsidiary of AstraZeneca Pharmaceuticals AB.

Valuation

Market Cap
β‚Ή0.00
β€”
Current Price
β‚Ή0
β€”as of 26 Aug 2026
P/E Ratio
0.0x
β€”
P/B Ratio
0.0x
β€”
EV / EBITDA
0.0x
β€”
EV / Sales
0.0x
β€”
52W High
β‚Ή0
β€”
52W Low
β‚Ή0
β€”
Shares Out
0.00 Cr
β€”

Profitability

Operating Margin
0.0%
β€”
Net Profit Margin
0.0%
β€”
EBITDA Margin
0.0%
β€”

Returns

ROE
0.0%
β€”
ROCE
0.0%
β€”
ROIC %
β€”
β€”
ROA
0.0%
β€”
Dividend Payout
0.0%
β€”

Solvency

Current Ratio
0.0x
β€”
Debt / Equity
0.0x
β€”
Debt / Assets
0.0x
β€”
CFO / Net Profit
0.0x
β€”
Interest Coverage
0.0x
β€”

AI Summary

Indian Stock

Sign up free to view AI insights

Get Started

Rule-based from financial data. Not advice.

Price Historyβ–Ό 10.72% over 1Y
Monthly Returns

Historically, Sep has averaged the highest return (+7.0%); Feb the lowest (-5.5%).

Average from:
YearJanFebMarAprMayJunJulAugSepOctNovDec
2026-5.3%Negative MonthJan 2026: -5.26%+3.6%Positive MonthFeb 2026: +3.59%-12.2%Negative MonthMar 2026: -12.25%+5.9%Positive MonthApr 2026: +5.90%+4.7%Positive MonthMay 2026: +4.71%-4.5%Negative MonthJun 2026: -4.51%-0.9%Neutral MonthJul 2026: -0.91%-12.1%*Negative MonthAug 2026: -12.11%β€”β€”β€”β€”
2025-1.1%Neutral MonthJan 2025: -1.13%-7.2%Negative MonthFeb 2025: -7.21%+28.3%Positive MonthMar 2025: +28.33%+0.7%Neutral MonthApr 2025: +0.69%-8.1%Negative MonthMay 2025: -8.08%+11.4%Positive MonthJun 2025: +11.38%+3.5%Positive MonthJul 2025: +3.50%-7.8%Negative MonthAug 2025: -7.76%+7.7%Positive MonthSep 2025: +7.66%+4.6%Positive MonthOct 2025: +4.58%-5.1%Negative MonthNov 2025: -5.11%-0.4%Neutral MonthDec 2025: -0.42%
2024+20.2%Positive MonthJan 2024: +20.24%-17.2%Negative MonthFeb 2024: -17.19%-3.2%Negative MonthMar 2024: -3.20%+0.4%Neutral MonthApr 2024: +0.39%+15.4%Positive MonthMay 2024: +15.37%+1.3%Neutral MonthJun 2024: +1.26%+12.7%Positive MonthJul 2024: +12.67%-6.3%Negative MonthAug 2024: -6.32%+21.0%Positive MonthSep 2024: +20.95%-4.5%Negative MonthOct 2024: -4.52%-13.7%Negative MonthNov 2024: -13.73%+11.4%Positive MonthDec 2024: +11.39%
2023+1.9%Neutral MonthJan 2023: +1.91%-0.2%Neutral MonthFeb 2023: -0.15%-3.1%Negative MonthMar 2023: -3.07%-1.8%Neutral MonthApr 2023: -1.77%+11.6%Positive MonthMay 2023: +11.56%+4.3%Positive MonthJun 2023: +4.33%+4.1%Positive MonthJul 2023: +4.08%+10.3%Positive MonthAug 2023: +10.30%+5.7%Positive MonthSep 2023: +5.68%+3.8%Positive MonthOct 2023: +3.77%+1.8%Neutral MonthNov 2023: +1.83%+16.0%Positive MonthDec 2023: +15.97%
2022-9.9%Negative MonthJan 2022: -9.86%-6.7%Negative MonthFeb 2022: -6.67%-2.0%Negative MonthMar 2022: -2.02%+7.8%Positive MonthApr 2022: +7.77%+9.4%Positive MonthMay 2022: +9.42%-10.3%Negative MonthJun 2022: -10.27%+13.3%Positive MonthJul 2022: +13.28%+0.2%Neutral MonthAug 2022: +0.16%+1.3%Neutral MonthSep 2022: +1.33%+6.0%Positive MonthOct 2022: +6.03%+2.6%Positive MonthNov 2022: +2.55%-2.6%Negative MonthDec 2022: -2.59%
2021β€”β€”β€”β€”β€”-4.4%Negative MonthJun 2021: -4.39%-6.6%Negative MonthJul 2021: -6.59%-7.8%Negative MonthAug 2021: -7.83%-0.5%Neutral MonthSep 2021: -0.54%-2.7%Negative MonthOct 2021: -2.66%+4.0%Positive MonthNov 2021: +3.98%-0.9%Neutral MonthDec 2021: -0.87%
AvgΒ±SD+1.2%Β±10.3%-5.5%Β±7.1%+1.6%Β±13.9%+2.6%Β±3.6%+6.6%Β±8.1%-0.4%Β±7.0%+4.3%Β±7.0%-3.9%Β±7.3%+7.0%Β±7.6%+1.4%Β±4.2%-2.1%Β±6.6%+4.7%Β±7.5%
* Current month β€” value will change until month-end.

Each cell is the percentage change in closing price from the end of the prior month to the end of this month. The bottom row shows the average return for that calendar month across the selected years, plus or minus one standard deviation β€” the range that historically contained roughly two-thirds of outcomes. Past monthly patterns are not a forecast of future returns.

Seasonal Tendency

This aggregates every month by calendar position β€” all Januaries together, all Februaries together, and so on β€” to show whether a given month has leaned positive or negative historically. β€˜Simple’ counts each month as +1 or βˆ’1. β€˜Weighted’ gives larger moves more influence: +2 above +10%, βˆ’2 below βˆ’10%. With only 6 years of history for this asset, each month’s score reflects a small number of observations β€” read it as a historical tendency, not a reliable seasonal pattern.

Historical Trend

This tracks a running tally across the asset’s full price history: each month adds or subtracts based on whether it was positive or negative. A rising line means more positive months than negative so far; a flattening or falling line means recent months have leaned negative. This measures historical month-to-month consistency, not expected future performance.

Year-to-Date ROI
Average from:
SD Γ—
Latest: 0.794x (2026)

Year-to-date return is calculated by dividing each day’s closing price by the price on January 1st of that year (or the asset’s first available price if it began trading mid-year). The custom average line shows the mean YTD return at each calendar day across the selected years. The standard deviation band shows the range within which returns have historically fallen β€” at 1 SD, roughly two-thirds of years; at 2 SD, roughly 95%. Past year-to-date patterns do not predict future returns. The average and standard deviation band are computed from the year set chosen in β€œAverage from”, which is independent of which year lines are displayed. The current in-progress year is excluded from these calculations, since a partial year is not comparable to complete ones. Election-cycle groupings follow the US presidential calendar and are offered only for US and crypto assets.

Historical Performance

Revenue, profitability, and cash flow trends (β‚Ή Crores)

Revenue (10Y)

Operating Income (10Y)

Net Profit (10Y)

Operating Margin % (10Y)

Dividend Payout % (10Y)

Free Cash Flow (10Y)

Growth Summary

Latest fiscal year: Mar 2025

Revenueβ‚Ή1.72 K Crβ–² 32.4%
EBITDA Growthβ€”
Net Profitβ‚Ή116.00 Crβ–Ό 28.4%
Cash from Ops (CFO)β€”
Free Cash Flow (FCF)β€”β–² 520.0%
Revenue CAGR 5Y9.3%
EBITDA CAGR 5Y11.9%
Net Profit CAGR 5Y17.6%
NP Growth 1Y-28.4%

Historical Growth

Year-by-year revenue, profitability, and cash flow (β‚Ή Crores, last 10 years)

YearRevenueOp. IncomeNet ProfitCFOFCFROERev Growth 1YNP Growth 1Y
Mar 2025β‚Ή1.72 K Crβ€”β‚Ή116.00 Crβ€”β€”15.1%32.4%-28.4%
Mar 2024β‚Ή1.30 K Crβ€”β‚Ή162.00 Crβ€”β€”22.8%29.2%63.6%
Mar 2023β‚Ή1.00 K Crβ€”β‚Ή99.00 Crβ€”β€”16.8%24.4%59.7%
Mar 2022β‚Ή806.00 Crβ€”β‚Ή62.00 Crβ€”β€”12.1%-1.0%-33.3%
Mar 2021β‚Ή814.00 Crβ€”β‚Ή93.00 Crβ€”β€”20.4%-2.2%29.2%
Mar 2020β‚Ή832.00 Crβ€”β‚Ή72.00 Crβ€”β€”19.8%14.3%33.3%
Mar 2019β‚Ή728.00 Crβ€”β‚Ή54.00 Crβ€”β€”17.9%27.5%107.7%
Mar 2018β‚Ή571.00 Crβ€”β‚Ή26.00 Crβ€”β€”10.5%5.0%30.0%
Mar 2017β‚Ή544.00 Crβ€”β‚Ή20.00 Crβ€”β€”9.0%-3.5%300.0%
Mar 2016β‚Ή564.00 Crβ€”β‚Ή5.00 Crβ€”β€”3.2%9.1%-123.8%

Financial Statements

Income statement, balance sheet, and cash flow (β‚Ή Crores, as reported)

Consolidated Figures in USD Millions.

Unnamed: 0Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025TTM
Revenue / Net Sales4745175645445717288328148061,0031,2961,7162,006
Total Expenses4875285475065256577116787198381,1111,4621,687
EBIT / Operating Profit-13-111637467112113586165184254320
OPM %-3%-2%3%7%8%10%15%17%11%16%14%15%16%
Other Income2367141216131315-1451-56-3
Finance Costs0000001111112
Depreciation & Amortisation10151716151519201716154046
Profit Before Tax0-21636447311412783134220156268
Tax %-0%9%44%41%25%37%27%26%26%26%26%-
Net Profit / PAT-1-21520265472936299162116199
EPS (β‚Ή)-0.20-8.342.108.0210.3621.7828.8837.3224.6439.7264.6046.3079.66
Dividend Payout %0%0%0%0%0%0%3%5%41%40%37%69%-

Peer Comparison

Healthcare sector peers, ranked by market cap

CompanyMarket CapRevenueP/EP/BEV/EBITDARev G 1Y
AstraZeneca Pharma India Ltd.this co.β‚Ή20.55 K Crβ‚Ή1.72 K Cr88.9025.7186.6032.4%
Sun Pharmaceutical Industries Ltd.β‚Ή4.15 L Crβ‚Ή23.00 K Cr88.7017.4372.3013.5%
Divi's Laboratories Ltd.β‚Ή1.71 L Crβ‚Ή9.20 K Cr67.9011.1367.2120.0%
Torrent Pharmaceuticals Ltd.β‚Ή1.33 L Crβ‚Ή9.68 K Cr62.5015.7645.6413.5%
Cipla Ltd.β‚Ή1.17 L Crβ‚Ή19.05 K Cr22.503.5119.3314.9%
Apollo Hospitals Enterprises Ltd.β‚Ή1.05 L Crβ‚Ή8.20 K Cr75.0011.2854.4412.8%
Max Healthcare Institute Limitedβ‚Ή1.00 L Crβ‚Ή2.66 K Cr144.0011.7696.8413.8%
Industry Averageβ€”β‚Ή3.29 K Cr98.638.1165.5020.2%

Learn while you research

Hand-picked academy chapters to deepen your understanding of AstraZeneca Pharma India Ltd. and the metrics that matter.

Browse the full Equiscale Academy